

Final - June 26, 2024

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 26-28, 2024

Wednesday, June 26, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:30	Respiratory Syncytial Virus Vaccines - Adult Introduction Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years Arexvy (GSK) immunogenicity with a 24-month revaccination interval	Dr. Camille Kotton (ACIP, WG Chair) Dr. Iona Munjal (Pfizer) Dr. Susan Gerber (GSK)
	mRNA-1345 (Moderna) Update on vaccine safety, efficacy and revaccination data Postmarketing safety updates: Vaccine Safety Datalink Evaluation of Guillain-Barre Syndrome (GBS) following RSV vaccination among adults 65 years and older	Dr. Rituparna Das (Moderna) Dr. James Donahue (Marshfield Clinic Research Institute) Dr. Patricia Lloyd (FDA)
10:00	Break	
10:10	RSV Vaccines - Adult (continued) Observational RSV vaccine effectiveness Economic analysis of adult RSV vaccination Update to benefits and risks discussion Comparison of economic analyses of adult RSV vaccination	Dr. Diya Surie (CDC, NCIRD) Dr. David Hutton (University of Michigan) Dr. David Hutton (University of Michigan) Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
11:30	Break	
11:40	RSV Vaccines - Adult (continued) Evidence to Recommendations Clinical Considerations	Dr. Michael Melgar (CDC/NCIRD), Lauren Roper (CDC/NCIRD), Dr. Amadea Britton (CDC/NCIRD) Dr. Michael Melgar (CDC/NCIRD)
1:05	Break	
1:50	Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®) Introduction EtR and proposed recommendations: Use of Vaxelis among American Indian and Alaska Native Infants Updated VFC resolution	Dr. Jamie Loehr (ACIP, WG Chair) Dr. Jennifer Collins (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD)
2:50	Break	
3:00	Public Comment	
3:20	VOTES Respiratory Syncytial Virus (RSV) Vaccines Votes Vaxelis Vaxelis VFC	Dr. Michael Melgar (CDC/NCIRD) Dr. Jennifer Collins (CDC/NCIRD) Dr. Jeanne Santoli (CDC/NCIRD)
4:10	Break	
4:20	Chikungunya Vaccine Introduction Update on chikungunya vaccines Epidemiology of chikungunya in U.S. territories and states Cost-effectiveness of use of live attenuated chikungunya vaccine among adults living in U.S. territories Next steps for Work Group	Dr. Wilbur Chen (ACIP, WG Chair) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Kelly Kilburn, Dr. Erin Staples (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
5:20	Dengue Vaccines Dengvaxia discontinuation Dengue vaccine updates	Dr. Nicholas Bergren (Sanofi) Dr. Joshua Wong (CDC/NCEZID)
5:30	Recess	

Final - June 26, 2024

Thursday, June 27, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC) <i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH</i>
8:15	Agency Updates	
8:35	COVID-19 Vaccine	
	Introduction	Dr. Matt Daley (ACIP, WG Chair)
	COVID-19-associated hospitalizations	Dr. Fiona Havers (CDC/NCIRD)
	COVID-19 vaccine effectiveness update	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Vaccine safety update for 2023-2024 COVID-19 vaccine	Dr. Jonathan Duffy (CDC/NCEZID)
	Economic analysis of COVID-19 vaccination	Dr. Lisa Prosser (University of Michigan)
	EtR for use of the 2024-2025 COVID-19 vaccine	Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
	COVID-19 vaccine implementation	Dr. Shannon Stokley (CDC/NCIRD)
11:05	Break	
11:20	Influenza Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Influenza A (H5N1) Update	Dr. Vivien Dugan (CDC/NCIRD)
12:00	Break	
1:00	Influenza Vaccines (continued)	
	WG Considerations and Proposed Recommendations	Dr. Lisa Grohskopf (CDC/NCIRD)
2:00	Pneumococcal Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Economic analysis and public health impact of PCV21 use in adults	Dr. Charles Stoecker (Tulane University)
	Comparison of economic analysis on PCV21 use in adults	Dr. Andrew Leidner (CDC/NCIRD)
	Summary of WG Interpretation of EtR and policy options on PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
	Clinical considerations for PCV21 use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
3:55	Break	
4:10	Public Comment	
4:30	<u>VOTES</u>	
	COVID-19	Dr. Megan Wallace (CDC/NCIRD)
	Pneumococcal	Dr. Miwako Kobayashi (CDC/NCIRD)
	Influenza	Dr. Lisa Grohskopf (CDC/NCIRD)
5:15	Recess	

Friday, June 28, 2024

8:30	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:55	Meningococcal Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Epidemiology Updates	Ms. Amy Rubis (CDC/NCIRD)
	GSK Pentavalent Vaccine Immunogenicity and Safety	Dr. Wendy Sohn (GSK)
	WG Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination	Dr. Sarah Schillie (CDC/NCIRD)
10:00	Break	
10:15	Respiratory Syncytial Virus Vaccines - Maternal/Pediatric	
	Introduction	Dr. Sarah Long (ACIP, WG Chair)
	Implementation and uptake of nirsevimab and maternal RSV vaccine	Dr. Shannon Stokley (CDC/NCIRD)
	Maternal RSV vaccine safety surveillance	Dr. Pedro Moro (CDC/NCEZID)
	Summary of effectiveness of nirsevimab in infants	Dr. Amanda Payne (CDC/NCIRD)
	Work Group considerations	Dr. Jefferson Jones, Dr. Katherine Fleming-Dutra (CDC/NCIRD)
11:40	Human papillomavirus Vaccines	
	Announcement of formation of an ACIP HPV vaccines work group	Dr. Oliver Brooks (ACIP, WG Chair)
11:50	Adjourn	

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
HPV	Human papillomavirus
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RSV	Respiratory Syncytial Virus (RSV)
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness